Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 25, Issue 1, 2015, Pages 96-105

  Lynn, Stephen ^a   Aartsma Rus, Annemieke ^a,b   Bushby, Kate ^a   Furlong, Pat ^c   Goemans, Nathalie ^d   De Luca, Annamaria ^e   Mayhew, Anna ^a   McDonald, Craig ^f   Mercuri, Eugenio ^g   Muntoni, Francesco ^h   Pohlschmidt, Marita ⁱ   Verschuuren, Jan ^b   Voit, Thomas ^j   Vroom, Elizabeth ^k   Wells, Dominic J ^l   Straub, Volker ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Parent Project Muscular Dystrophy   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CATHOLIC UNIVERSITY   (Italy)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ Muscular Dystrophy Campaign   (United Kingdom)

^j INSERM   (France)

^k Duchenne Parent Project   (Netherlands)

^l ROYAL VETERINARY COLLEGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 6; DRISAPERSEN; DYSTROPHIN; GELATINASE B; MICRORNA; STEROID;

AIR CONDITIONING; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE MARKER; DISEASE MODEL; DUCHENNE MUSCULAR DYSTROPHY; EXON; FUNCTIONAL ASSESSMENT; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SPINE SURGERY; TREATMENT RESPONSE; WORKSHOP; ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 84919859690     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.09.003     Document Type: Article

References (46)

1. Hoffman E.P. Genotype/phenotype correlations in Duchenne/Becker dystrophy. Mol Cell Biol Hum Dis Ser 1993, 3:12-36.
2. Willmann R., De Luca A., Benatar M., et al. Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul Disord 2012, 22:43-49.
3. Nagaraju K., Willmann R. Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zurich, June 30th-July 1st 2008. Neuromuscul Disord 2009, 19:502-506.
4. Willmann R., Possekel S., Dubach-Powell J., Meier T., Ruegg M.A. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 2009, 19:241-249.
5. Bladen C.L., Rafferty K., Straub V., et al. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat 2013, 34:1449-1457.
6. Rodger S., Lochmüller H., Tassoni A., et al. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J Rare Dis 2013, 8:171.
7. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010, 9:177-189.
8. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9:77-93.
9. Sejerson T., Bushby K. Standards of care for Duchenne muscular dystrophy: brief TREAT-NMD recommendations. Adv Exp Med Biol 2009, 652:13-21.
10. Muntoni F. The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul Disord 2010, 20:355-362. Meeting Steering Committee, TREAT-NMD NetworkTREAT-NMD Network.
11. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
12. McDonald C.M., Henricson E.K., Han J.J., et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010, 41:500-510.
13. McDonald C.M., Henricson E.K., Han J.J., et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 2010, 42:966-974.
14. McDonald C.M., Henricson E.K., Abresch R.T., et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 2013, 48:357-368.
15. McDonald C.M., Widman L.M., Walsh D.D., Walsh S.A., Abresch R.T. Use of step activity monitoring for continuous physical activity assessment in boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil 2005, 86:802-808.
16. Goemans N., van den Hauwe M., Wilson R., van Impe A., Klingels K., Buyse G. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord 2013, 23:618-623.
17. Mazzone E., Martinelli D., Berardinelli A., et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010, 20:712-716.
18. Ricotti V., Ridout D.A., Scott E., et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2013, 84:698-705.
19. McDonald C.M., Henricson E.K., Abresch R.T., et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 2013, 48:343-356.
20. Mazzone E.S., Pane M., Sormani M.P., et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS ONE 2013, 8:e52512.
21. Henricson E., Abresch R., Han J.J., et al. The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Currents 2013, 5. 10.1371/currents.md.9e17658b007eb79fcd6f723089f79e06.
22. McDonald C.M., McDonald D.A., Bagley A., et al. Relationship between clinical outcome measures and parent proxy reports of health-related quality of life in ambulatory children with Duchenne muscular dystrophy. J Child Neurol 2010, 25:1130-1144.
23. Scott E., Eagle M., Mayhew A., et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 2012, 17:101-109.
24. Mazzone E.S., Messina S., Vasco G., et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 2009, 19:458-461.
25. Mayhew A., Cano S., Scott E., Eagle M., Bushby K., Muntoni F. On behalf of The North Star Clinical Network for Paediatric Neuromuscular Disease. Moving towards meaningful measurement: Rasch Analysis of North Star Ambulatory Assessment in Duchenne muscular dystrophy. Developmental Medicine & Child Neurology 2011, 53:535-542.
26. Mayhew A.G., Stefan J., Cano S.J., et al. The North Star Clinical Network for Neuromuscular Disease. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Developmental Medicine & Child Neurology 2013, 55:1046-1052.
27. Mayhew A., Mazzone E.S., Eagle M., et al. Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 2013, 55:1038-1045.
28. Pane M., Mazzone E.S., Fanelli L., et al. Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord 2014, 24:201-206.
29. Lyager S., Steffensen B., Juhl B. Indicators of need for mechanical ventilation in Duchenne muscular dystrophy and spinal muscular atrophy. Chest 1995, 108:779-785.
30. Abresch R.T., Carter G.T., Han J.J., McDonald C.M. Exercise in neuromuscular diseases. Phys Med Rehabil Clin N Am 2012, 23:653-673.
31. Servais L., Deconinck N., Moraux A., et al. Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul Disord 2013, 23:139-148.
32. van Putten M., Hulsker M., Young C., et al. The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS ONE 2012, 7:e31937.
33. Sharp P.S., Bye-a-Jee H., Wells D.J. Physiological characterisation of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Molecular Therapy 2011, 19:165-171.
34. Aartsma-Rus A., Ferlini A., Vroom E. Biomarkers and surrogate endpoints in Duchenne: meeting report. Neuromuscul Disord 2014, 24:743-745.
35. Nadarajah V.D., van Putten M., Chaouch A., et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscular Disord 2011, 21:569-578.
36. Hu J., Kong M., Ye Y., Hong S., Cheng L., Jiang L. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy. J Neurochem 2014, 129:877-883.
37. Mizuno H., Nakamura A., Aoki Y., et al. Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS ONE 2011, 6:e18388.
38. Vignier N., Amor F., Fogel P., et al. Distinctive serum miRNA profile in mouse models of striated muscular pathologies. PLoS ONE 2013, 8:e55281.
39. Zaharieva I.T., Calissano M., Scoto M., et al. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy. PLoS ONE 2013, 8:e80263.
40. Hollingsworth K.G., Garrood P., Eagle M., Bushby K., Straub V. Magnetic resonance imaging in Duchenne muscular dystrophy: longitudinal assessment of natural history over 18 months. Muscle Nerve 2013, 48:586-588.
41. Finanger E.L., Russman B., Forbes S.C., Rooney W.D., Walter G.A., Vandenborne K. Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am 2012, 23:1-10. ix.
42. Fischmann A., Hafner P., Gloor M., et al. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J Neurol 2013, 260:969-974.
43. Forbes S.C., Lott D.J., Finkel R.S., et al. MRI/MRS evaluation of a female carrier of Duchenne muscular dystrophy. Neuromuscul Disord 2012, 22(Suppl. 2):S111-S121.
44. Willcocks R.J., Arpan I.A., Forbes S.C., et al. Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord 2014, 24:393-401.
45. Franson T.R., Peay H. Benefit-risk assessments in rare disorders. Parent Project Muscular Dystrophy. <>. http://bit.ly/1o8Ggna.
46. Pane M., Mazzone E.S., Sormani M.P., et al. 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS ONE 2014, 9(1):e83400.